Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat

被引:12
作者
Bergstrom, P
Johnsson, A
CavallinStahl, E
Bergenheim, T
Henriksson, R
机构
[1] UNIV LUND HOSP,DEPT ONCOL,S-22185 LUND,SWEDEN
[2] UMEA UNIV HOSP,DEPT NEUROSURG,S-90185 UMEA,SWEDEN
关键词
glioma; chemotherapy; cisplatin; amphotericin B; DNA adducts; renal toxicity;
D O I
10.1016/S0959-8049(96)00339-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an attempt to modify the cytotoxicity of cisplatin, amphotericin B (AmB) was given as pretreatment to BDIX rats with intracerebral BT4C glioma implants. Ten animals given AmB 5 mg/kg i.p. followed by cisplatin 5 mg/kg i.p. displayed massive haematuria within 24 h after treatment and died a few days later. The antitumoral effect could not, therefore, be evaluated. Histopathological examination of the kidneys showed extensive tubular necrosis. No signs of apoptotic cell death were found using in situ end labelling with biotin-labelled nucleotides or with DNA integrity analysis in agarose gel electrophoresis. An immunohistochemical method for analysis of cisplatin-DNA adducts was used to elucidate the distribution of cisplatin in brain tumour, normal brain and kidney. Addition of AmB to cisplatin caused increased adduct formation in kidneys, particularly in tubular cells. It seems plausible that the nephrotoxicity, at least in part, was mediated by increased levels of cisplatin-DNA adducts. Pretreatment with AmB did not have any obvious effect on the formation of adducts in the cerebral cortex. The adduct levels in the tumours from animals pretreated with AmB were not significantly increased compared with those treated with cisplatin only. Thus, addition of AmB to cisplatin caused excessive nephrotoxicity suggesting a decrease in the therapeutic ratio of cisplatin. (C) 1997 Published by Elsevier Science Ltd.
引用
收藏
页码:153 / 159
页数:7
相关论文
共 34 条
[1]   OPTICAL MICROSCOPE SYSTEM FOR STANDARDIZED CELL MEASUREMENTS AND ANALYSES [J].
BACUS, JW ;
GRACE, LJ .
APPLIED OPTICS, 1987, 26 (16) :3280-3293
[2]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[3]  
BERGENHEIM AT, 1994, INT J ONCOL, V5, P293
[4]  
BERGSTROM P, 1991, ANTICANCER RES, V11, P1039
[5]  
BLOMMAERT, 1996, THESIS NETHERLANDS C
[6]   TOPICAL AND SYSTEMIC ANTIFUNGAL AGENTS [J].
BODEY, GP .
MEDICAL CLINICS OF NORTH AMERICA, 1988, 72 (03) :637-659
[7]   POTENTIATION OF ANTIMETABOLITE ANTITUMOR-ACTIVITY INVIVO BY DIPYRIDAMOLE AND AMPHOTERICIN-B [J].
CAO, SS ;
ZHEN, YS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (03) :181-186
[8]  
DIVE C, 1993, FRONTIERS PHARM CANC, P21
[9]  
EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275
[10]  
FICHTINGERSCHEPMAN AMJ, 1989, CANCER RES, V49, P2862